Analysis of the main effects and common side effects of ceritinib

Ceritinib is a targeted therapy drug mainly used to treat patients with non-small cell lung cancer (NSCLC) whose ALK gene rearrangement is positive. This drug is a targeted inhibitor that can prevent the proliferation and spread of cancer cells by inhibiting the activity of the ALK enzyme. Rearrangements of the ALK (anaplastic lymphoma kinase) gene are common in some patients with non-small cell lung cancer, and ceritinib offers an effective treatment option for this specific type of cancer by targeting this mutated protein.

Ceritinib, as an oral drug, can effectively target and inhibit the ALK protein in tumor cells during treatment, thereby achieving the effect of controlling disease progression. Compared with traditional chemotherapy drugs, ceritinib has fewer side effects and is more targeted, which means it is more targeted and can effectively reduce damage to normal cells.

However, although ceritinib has shown significant efficacy in the treatmentALK-positive non-small cell lung cancer, its use is also accompanied by certain side effects. Common side effects include but are not limited to gastrointestinal discomfort, such as nausea, vomiting, diarrhea, etc. Some patients may also experience loss of appetite or weight loss. In addition, abnormal liver function, fatigue, and respiratory symptoms such as cough and dyspnea are also common adverse reactions reported by patients.

In some cases, patients may experience more serious side effects, such as severe liver damage or electrocardiogram abnormalities (QT interval prolongation). Therefore, during treatment with ceritinib, patients need to undergo regular liver function and electrocardiogram tests to ensure that the drug does not cause unacceptable toxic reactions. If serious side effects occur, patients should contact their doctor immediately, which may require a dose adjustment or discontinuation of the drug.

Reference materials:https://go.drugbank.com/drugs/DB09063